85 results on '"Devous, Michael D."'
Search Results
2. Topographic staging of tau positron emission tomography images
3. Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials
4. Dopamine efflux in response to ultraviolet radiation in addicted sunbed users
5. Revolutionizing Alzheimer's disease and clinical trials through biomarkers
6. The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET
7. Risk factors for mild cognitive impairment among Mexican Americans
8. Striatal–limbic activation is associated with intensity of anticipatory anxiety
9. Effects of beta-amyloid accumulation on neural function during encoding across the adult lifespan
10. A comprehensive reliability assessment of quantitative diffusion tensor tractography
11. Neural response to lidocaine in healthy subjects
12. Abnormal brain response to cholinergic challenge in chronic encephalopathy from the 1991 Gulf War
13. Sex differences in medial and lateral orbitofrontal cortex hypoperfusion in cocaine-dependent men and women
14. A SPECT study of language and brain reorganization three years after pediatric brain injury
15. Single-Photon Emission Computed Tomography in Neurotherapeutics
16. Gender differences in limbic responsiveness, by SPECT, following a pharmacologic challenge in healthy subjects
17. Dose-response measures of rCBF and subjective changes following procaine in healthy female volunteers
18. A SPECT HMPAO study of regional cerebral blood flow in depressed adolescents and normal controls
19. TEMPORAL LOBE QUANTITATION OF FLORTAUCIPIR PET IMAGES MAY IMPROVE DETECTION OF INTERMEDIATE NEUROFIBRILLARY TANGLE PATHOLOGY IN AUTOPSY-VALIDATED CASES
20. EARLY TAU DETECTION AND IMPLICATIONS FOR DISEASE PROGRESSION
21. ASSOCIATION BETWEEN APOE ISOFORM AND 18-MONTH TAU ACCUMULATION
22. RELATIONSHIPS BETWEEN FLORTAUCIPIR TAU BINDING AND REGIONAL BRAIN ATROPHY IN AMYLOID POSITIVE SUBJECTS ACROSS THE ALZHEIMER’S DISEASE SPECTRUM
23. RELATIONSHIPS BETWEEN FLORTAUCIPIR TAU BINDING AND REGIONAL BRAIN ATROPHY IN AMYLOID POSITIVE SUBJECTS ACROSS THE ALZHEIMER’S DISEASE SPECTRUM
24. IMPLEMENTATION OF DUAL-PHASE FLORBETAPIR PET IN THE MULTICENTER PHASE 2 NAVIGATE-AD CLINICAL TRIAL
25. LOBAR CLASSIFICATION OF TAU PET IMAGES IN THE EXPEDITION-3 TRIAL
26. LOBAR CLASSIFICATION OF TAU PET IMAGES IN THE EXPEDITION-3 TRIAL
27. MODELING OF TAU TRAJECTORIES ACROSS THE ALZHEIMER’S DISEASE SPECTRUM USING [18F]-FLORTAUCIPIR PET IMAGING
28. PET BIOMARKERS IN THE EXPEDITION 3 TRIAL OF PATIENTS WITH MILD AD
29. A ROBUST, SIMPLIFIED BRAAK-TYPE CLASSIFICATION SCHEME FOR FLORTAUCIPIR F-18 TAU PET IMAGES
30. PARAMETRIC IMAGING OF TAU LOAD IN ALZHEIMER’S PATIENTS AND CONTROLS USING FLORTAUCIPIR
31. THE ASSOCIATION OF TAU BURDEN IN CEREBRAL LOBES AND FUNCTIONAL BRAIN NETWORKS WITH PERFORMANCE IN DIFFERENT COGNITIVE DOMAINS
32. THE ASSOCIATION OF TAU BURDEN IN CEREBRAL LOBES AND FUNCTIONAL BRAIN NETWORKS WITH PERFORMANCE IN DIFFERENT COGNITIVE DOMAINS
33. PARAMETRIC IMAGING OF TAU LOAD IN ALZHEIMER’S PATIENTS AND CONTROLS USING FLORTAUCIPIR
34. A ROBUST, SIMPLIFIED BRAAK-TYPE CLASSIFICATION SCHEME FOR FLORTAUCIPIR F 18 TAU PET IMAGES
35. COMPARISON OF REGIONAL FLORTAUCIPIR PET TO QUANTITATIVE TAU AND AMYLOID IMMUNOASSAY IN PATIENTS WITH ALZHEIMER’S DISEASE PATHOLOGY: A PILOT CLINICO-PATHOLOGICAL STUDY
36. QUANTIFICATION OF TAU LOAD USING [18F]AV-1451 AND PET
37. DIFFERENTIATING PRECLINICAL ALZHEIMER’S DISEASE FROM NORMAL AGING: THE EFFECTS OF AGE AND AMYLOID ON COGNITIVE DECLINE OVER 3.5 YEARS
38. CONVERSION OF AMYLOID QUANTITATION WITH FLORBETAPIR SUVR TO THE CENTILOID SCALE
39. SAFETY, PHARMACOKINETICS (PK), AND FLORBETAPIR F-18 POSITRON EMISSION TOMOGRAPHY (PET) AFTER MULTIPLE DOSE ADMINISTRATION OF LY3002813, A β-AMYLOID PLAQUE-SPECIFIC ANTIBODY, IN ALZHEIMER’S DISEASE (AD)
40. EVOLUTION OF [18F]AV-1451 PET TAU SIGNAL: INTERIM ANALYSIS OF AN 18-MONTH PHASE 2 STUDY
41. THE RELATIONSHIP OF [18F]AV-1451 PET TAU IMAGES TO CHANGES IN COGNITION OVER TIME
42. IMAGE PATTERNS AND CLINICAL PHENOTYPES ASSOCIATED WITH FASTEST INCREASE OF TAU BURDEN MEASURED BY LONGITUDINAL [18F]-AV-1451 (T807) PET STUDIES
43. QUANTIFICATION OF TAU LOAD USING [18F]AV-1451 AND PET
44. IMAGE PATTERNS AND CLINICAL PHENOTYPES ASSOCIATED WITH FASTEST INCREASE OF TAU BURDEN MEASURED BY LONGITUDINAL [18F]-AV-1451 (T807) PET STUDIES
45. DIFFERENTIATING PRECLINICAL ALZHEIMER’S DISEASE FROM NORMAL AGING: THE EFFECTS OF AGE AND AMYLOID ON COGNITIVE DECLINE OVER 3.5 YEARS
46. CONVERSION OF AMYLOID QUANTITATION WITH FLORBETAPIR SUVR TO THE CENTILOID SCALE
47. A randomized, controlled, multicenter, international study of the impact of florbetapir (18F) PET amyloid imaging on patient management and outcome
48. Relationships between cognitive assessments and spatial distribution of neuropathological tau as assessed by 18F AV-1451 PET scanning
49. Region-dependent kinetics of the Tau PET tracer [18 F]-AV-1451 (T807)
50. Understanding the topology of 18F-AV-1451 (also known as T807) PET tau images in Alzheimer’s disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.